作为心力衰竭缓解和心肌恢复的催化剂的LVAD治疗
Eman A Hamad1, Mirnela Byku2, Sharon B Larson3
1Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Clinical cardiology
|August 1, 2023
概括
心力衰竭管理的重大进展,包括左心室辅助装置 (LVAD),现在允许心肌恢复. 这使得潜在的设备扩展和持续的患者恢复成为可能.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 心脏衰竭研究研究
背景情况:
- 慢性心力衰竭的管理已经显著发展.
- 左心室辅助器件 (LVAD) 是一个关键的治疗选择.
- 心肌恢复越来越被认为是一种可能性.
研究的目的:
- 审查心力衰竭医疗优化方面的进展.
- 讨论评估LVAD患者心肌恢复的策略.
- 总结LVAD移除后的探索方法和结果.
主要方法:
- 医学优化和设备治疗的文献综述.
- 对心肌逆向重塑研究的分析.
- 检查LVAD实验和后实验结果的技术.
主要成果:
- 医疗优化和卸载可以促进心肌恢复.
- 结构,分子和血液动力学改进对于恢复至关重要.
- 在精选的患者中,可以成功实现LVAD扩展.
结论:
- 心肌恢复是心力衰竭管理的一个可行的目标.
- LVAD疗法可以促进恢复,可能导致扩散.
- 对评估和解释策略的进一步研究是有必要的.
相关概念视频
Cardiomyopathy V: Interprofessional Care
16
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463


